Apogee Therapeutics, Inc.

NasdaqGM APGE

Apogee Therapeutics, Inc. Dividend Per Share for the Trailing 12 Months (TTM) ending September 30, 2024: USD -0.00

Apogee Therapeutics, Inc. Dividend Per Share is USD -0.00 for the Trailing 12 Months (TTM) ending September 30, 2024. Dividend per share represents the dividends distributed per share. Indicates dividend yield potential on a per-share basis.
Key data
Date Dividend Per Share Free Cash Flow Per Share Return on Assets (ROA) Return on Equity (ROE)
Market news
Loading...
SV Wall Street
NasdaqGM: APGE

Apogee Therapeutics, Inc.

CEO Dr. Michael Thomas Henderson M.D.
IPO Date July 14, 2023
Location United States
Headquarters 221 Crescent Street
Employees 91
Sector Healthcare
Industries
Description

Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.

StockViz Staff

February 4, 2025

Any question? Send us an email